Rapport Therapeutics (RAPP) said Friday that data from a proof-of-concept study of RAP-219 showed a link between a seizure biomarker and clinical seizures.
The data showed that a 30% reduction in long episode frequency was associated with a decrease of at least 50% in clinical seizures, regardless of the antiseizure medication used, according to the company.
This sets the benchmark for evaluating the potential efficacy of antiseizure treatments, including RAP-219, the company said.
Price: 20.17, Change: -0.11, Percent Change: -0.52
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。